Agree that it is good to get some clarity on revised timetables, specially when there are significant delays.
Agree also with Dogman, Bio plays (specially early ones and pre-revenue) are notoriously long plays and volatile at the best of times.
Look how long it took to get RRV and CHIK-V peer review , I remember a few posters on here commenting that they were worried about the whole RRV program as we hadn't had an update for so long...OA 2B I'm sure isn't too far away but I too have heard it has been exceptionally delayed due to peer reviewers having their work cut out for them due to all the Covid studies.
Ann: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION, page-253
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.005(2.00%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $187.1K | 755.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 47906 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 13363 | 1 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |